One person's headache is another person's market share. According to a report from pharmaceutical and health-care researchers Decision Resources Inc., Waltham, Mass., the migraine drug market will double from $2.86 billion in 2002 to about $5.6 billion in 2012 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. The triptan drug class will hold 75% market share through 2012, the report also states. (AstraZeneca and GlaxoSmithKline have products in this category). In these seven markets, more than 74 million people suffered from migraines in 2002, the company reports, but up to 65% of those afflicted in these markets remain undiagnosed. Diagnosis rates are on the rise, however, due to advertising campaigns from the drug makers and other awareness campaigns.